What's Inside


HOT Home

University of Minnesota Physicians Clinic Appointment and Referral Information


 

 
  Home > Faculty > Arkadiusz Dudek, M.D., Ph.D.
 

Arkadiusz Dudek, M.D., Ph.D.

Associate ProfessorDOMHOT_Faculty_Dudek09

Leader, Solid Tumor Oncology
Cancer Experimental Therapeutics Initiative,
Masonic Cancer Center


Mailing Address:
Medicine - Hematology, Oncology and Transplantation Office
MMC 480 Mayo
420 Delaware
Minneapolis, MN 55455

Phone: (612) 624-0123
Fax: (612) 625-6919
Email: dudek002@umn.edu
Preferred method of contact: email

Areas of Expertise

  • Tumor Angiogenesis
  • Malignant Melanoma Biology
  • Kidney Cancer Biology
Biography

Dr. Dudek received his M.D. in 1989 from the Medical Academy, University of Warsaw, Poland. He received Internal Medicine residency training in Harrisburg, Pennsylvania and subsequently trained in Hematology, Oncology and Transplantation at the University of Minnesota before joining the faculty in 1997. He received his Ph.D. from Military Medical Academy of Warsaw in 1998.
 

Research Interests
Dr. Dudek's clinical interest is focused on the management of thoracic malignancies, but includes the treatment of malignant hematologic disorders, malignant melanoma, kidney cancer and blood and marrow transplantation. His clinical research interests include phase I and II clinical trials in solid tumors. His laboratory research is focused on cancer angiogenesis.
 
Academic Distinctions
  • Fellow, American College of Physicians (1999)
  • University of Minnesota Cancer Center Award of Recognition for outstanding contribution to the Cancer Center mission (2004)
  • University of Minnesota Cancer Center Clinical Scholar Award (2005-2007)
  • University of Minnesota, Department of Medicine Clinical Excellence Award (2005)
  • American Medical Association: Physicians’ Recognition Award (2006-2009)
  • Hematology, Oncology, and Transplantation Fellowship Program: Outstanding Academic Mentor Award
Selected Publications
Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet Factor 4 Binds To Glycanated Forms of Thrombomodulin and To Protein C; A Potential Mechanism for Enhancing a Generation of Activated Protein C. Journal of Biological Chemistry, 272(50):31785-92;Dec 12 1997.

Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. The Journal of Clinical Investigation, 109:337-346;Feb 2003.

Dudek AZ, Verfaillie CM, Nesmelova I, Mayo K, Pitchford S, Slungaard A. Platelet Factor 4 Promotes Adhesion of Hematopoietic Progenitors Cells And Binds Interleukin 8: Novel Mechanisms of Modulation of Hematopoiesis. Blood. 101(12):4687-4694;Jun 15 2003.

Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis Obliterans In Recipients Of Bone Marrow Transplantation: Analysis of Risk Factors And Treatment Outcomes. Biology of Blood and Bone Marrow Transplantation. 9(10):657-666;Oct 2003.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ and Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May 20;25(15):2078-85.

Dudek AZ, Bodempudi V, Milbauer L , Griffin RJ , Hebbel RP. Systemic Inhibition of Tumor Angiogenesis by endothelial cell-based gene therapy. British Journal of Cancer (2007) 97, 513 – 522.

Dudek AZ, Yunis C, Harrison L, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. First in human phase I trial of 852A a novel systemic Toll-Like Receptor 7 agonist to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 13 (23) December 1, 2007.

Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK. Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. J Thorac Oncol. 2008 Apr;3(4):394-399.

Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol. 2008 Apr;31(2):173-81.

Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer. 2009 May 5;100(9):1379-84.

Wcislo R, Dzwinel W, Yuen DA, Dudek AZ. A 3-D model of tumor progression based on complex automata driven by particle dynamics. J Mol Model. 2009 Dec;15(12):1517-39. Epub 2009 May 23.

Dudek AZ, Lesniewski-Kmak K, Larson T, Dragnev K, Isaksson R, Gupta V, Maddaus MA, Kratzke RA. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.J Thorac Oncol. 2009 Aug;4(8):969-75.

Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res. 2009 Oct 1;15(19):6137-47. Epub 2009 Sep 29.

Dudek AZ, Yee RT, Manivel JC, Isaksson R, Yee HO. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Anticancer Res. 2010 Mar;30(3):987-92. 

Bodempudi V, Ohlfest JR, Terai K, Zamora EA, Vogel RI, Gupta K, Hebbel RP, Dudek AZ. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Therapy 2010; 17(12):855-63. PMID: 20725100

Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant. 2011; 25(4):541-8. PMID: 21050273

Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011; 117(10):2202-8. PMID: 21523734

Zhang H, Li W, Franklin MJ, Dudek AZ.  Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis.  Anticancer Res. 2011 Nov;31(11):3945-52.  PMID: 22110224

Wang H, Cao Q, Dudek AZ.  Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.  Anticancer Res. 2012; 32(3):1027-31.  PMID: 22399627

Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL; Cancer and Leukemia Group B.  Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012; 7(4):755-9.  PMID: 22425926

Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA.  Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.  Lancet Oncol. 2012; 13(5):539-48. PMID: 22452895

Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olyaee MS, Esfandyari T, Farassati F.  Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One. 2012;7(4):e33214. PMID: 22485139

Chi M, Dudek AZ, Wind KP.  Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors.  Onkologie. 2012; 35(4):210-4.  Review.  PMID: 22488093

Yoseph B, Chi M, Truskinovsky AM, Dudek AZ. Large-cell neuroendocrine carcinoma of the cervix. Rare Tumors. 2012; 4(1):e18. PMID: 22532916

Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA.  A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2012 Jul 16. [Epub ahead of print]  PMID: 22809813

Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK.  Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics. 2012; 13(9):1009-21. PMID: 22838949

Dudek AZ, Gupta K, Ramakrishnan S, Mukhopadhyay D.  Tumor angiogenesis 2012.  J Oncol. 2012;2012:857383. PMID: 22919384

 

 

 

 

Feedback | Notice of Privacy Practices